October 28, 2026
Expanding Opportunities for Women to Lead Cardiovascular Science
Alnylam is working with Women As One, an organization dedicated to advancing opportunities for women in cardiology. Together, we support mentorship, research
Read More ›
October 24, 2026
Celebrating Caregivers – "The People Who Keep Showing Up for You"
Read Ester's story and insights on caregiving while living with hereditary ATTR amyloidosis, including lessons on resilience, support, and self-care.
Read More ›
October 15, 2026
The Signs Were There: How Pete Shaw and His Team Faced an Unexpected Opponent
For former professional football player Pete Shaw, recognizing the signs of hATTR-CM meant looking beyond the expected. Read his story and path to answers.
Read More ›
August 26, 2026
Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM
For patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the path to effective care often begins with a challenge: receiving the right diagnosis before the disease irreversibly advances.
Read More ›
March 27, 2026
Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ...
TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease.
Read More ›
September 6, 2023
First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR Am ...
The Amyloidosis Alliance has published the first-ever consensus recommendations for patient- and family-centred holistic care in ATTRv.
Read More ›
September 6, 2021
Co-Creating with Patients, for Patients: Addressing Unmet Needs in Conversations about AT ...
Collaborating with patient organizations and patients is an essential part of our efforts to support people living with a complex rare disease like...
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site